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In Brief Zou et al. show that PF-06463922, an ALK/ROS1 inhibitor, is effective against all known clinical ALK mutants. Moreover, PF-06463922 is effective against brain metastases of EML4-ALK-driven tumors and has high safety margins in preclinical studies.
INTRODUCTION
The clinical success of targeting oncogenic tyrosine kinases that are genetically altered through activating mutations, gene translocations, or gene amplification has launched a new era of cancer therapy (Weinstein, 2002) . However, acquired resistance is a major limitation to the efficacy of tyrosine kinase inhibitors (TKIs) in the clinic (Bagrodia et al., 2012; Lackner et al., 2012; Rosenzweig, 2012) . Crizotinib, a small-molecule inhibitor of the MET, ALK, and ROS1 tyrosine kinases, is highly active in lung cancers harboring chromosomal rearrangements of ALK or ROS1. In ALK-positive non-small-cell lung cancer (NSCLC) patients, crizotinib demonstrated an objective response rate of about 60% and a median progression-free survival of approximately 8 to 11 months Gerber and Minna, 2010; Kwak et al., 2010; Solomon et al., 2014c) . Similar to the experience with other TKIs, several resistance mechanisms have been observed in patients who relapse on crizotinib. These resistance mechanisms include secondary ALK kinase domain mutations (Choi et al., 2010; Doebele et al., 2012; Katayama et al., 2011 Katayama et al., , 2012 Sasaki et al., 2011) ; ALK gene amplification Katayama et al., 2012; Kim et al., 2013) ; bypass downstream signaling via EGFR (Katayama et al., 2012; Sasaki et al., 2011; Tanizaki et al., 2012) , KIT (Katayama et al., 2012) , SRC , or IGF-1R (Lovly et al., 2014) ; and pharmacological resistance Significance Though the development of ALK inhibitors has changed the course of treatment in NSCLC patients, tumors invariably relapse. Here, we demonstrate the superior properties of the next-generation ALK inhibitor PF-06463922 compared with clinically available ALK inhibitors. PF-06463922 addresses two major mechanisms of clinical relapse, ALK resistance mutations and brain metastasis. Superior potency, selectivity, and physicochemical properties of PF-06462922 are reflected in its ability to achieve potent inhibition of all tested ALK resistance mutations, to penetrate the CNS, and to regress brain metastasis, while having robust safety margins in preclinical studies. PF-06463922 has the potential to treat ALK-driven cancer in both the refractory and the frontline settings.
due to sub-optimal CNS exposure (Costa et al., 2011; Gandhi et al., 2013; Maillet et al., 2013; Weickhardt et al., 2012) . Roughly 30% of crizotinib-refractory tumors have been shown to harbor resistance mutations in the ALK kinase domain, including G1269A, L1196M, C1156Y, L1152R, S1206Y, 1151Tins, G1202R, and F1174L (Gainor and Shaw, 2013) . Although crizotinib has shown clinical activity against brain metastases (Costa et al., 2013; Kaneda et al., 2013; Kinoshita et al., 2013; Takeda et al., 2013) , progression in the brain is particularly common in relapsed patients (Costa et al., 2015; Weickhardt et al., 2012) .
Recently, the second-generation ALK inhibitors ceritinib and alectinib have been approved for use in crizotinib-relapsed ALK-fusion-positive NSCLC patients in the United States and for ALK-fusion-positive crizotinib-naive NSCLC patients in Japan, respectively (Chen et al., 2013; Gadgeel et al., 2014; Kinoshita et al., 2012; Shaw et al., 2014a) . Although both ALK inhibitors show efficacy in these settings, resistance to both of these inhibitors has emerged. In the case of ceritinib, relapsed tumors often express the ALK mutant G1202R . In the case of alectinib, in addition to G1202R, two ALK resistance mutations (V1180L and I1171T) have been observed (Ignatius Ou et al., 2014; Katayama et al., 2014) . Some ALK mutants such as G1202R confer high-level resistance to all clinically available ALK inhibitors Ignatius Ou et al., 2014; Shaw and Engelman, 2013 Values are presented as mean ± SD (n = 3). See also Figure S1 and Table S1 .
alectinib showed a CNS response rate of 52% (Gadgeel et al., 2014) . Despite the observed CNS activity with these agents, it remains common for patients to relapse with CNS progression. A full understanding of the activity of clinically available ALK inhibitors on brain metastases is still emerging, and we provide a glimpse into mechanisms for their resistance here. We initiated a drug discovery program with the goal of developing a next-generation ALK inhibitor that is more potent and selective than other known ALK inhibitors (including current second-generation inhibitors), capable of inhibiting all known resistant ALK mutants and able to penetrate the blood-brain barrier (BBB) to achieve therapeutic CNS drug concentrations. PF-06463922, an ATP-competitive small-molecule inhibitor of ALK/ROS1, was successfully discovered by the optimization of physicochemical properties guided by structure-based drug design . Here we investigate the preclinical antitumor activity of PF-06463922 in both subcutaneous and intracranial tumor models.
RESULTS
PF-06463922 Has Sub-nanomolar Biochemical and Nanomolar Cellular Potency against Wild-Type and Crizotinib-Resistant ALK Mutants PF-06463922 is a potent, reversible, ATP-competitive inhibitor of recombinant ALK kinase ( Figure S1A ). In biochemical assays, PF-06463922 inhibited the catalytic activity of recombinant human wild-type ALK with a mean K i of <0.07 nM ( Figure 1A ). In addition, PF-06463922 showed a range of mean K i values of <0.1 to 0.9 nM against the following crizotinib-resistant ALK mutants: L1196M, G1269A, 1151Tins, F1174L, C1156Y, L1152R, and S1206Y. PF-06463922 was more potent than crizotinib, ceritinib, and alectinib against wild-type ALK in biochemical studies ( Figure 1B ). In addition to its high potency against ALK, PF-06463922 has previously demonstrated subnanomolar cell potency against ROS1 (Zou et al., 2015) and demonstrated >100-fold selectivity versus non-target kinases, relative to the ALK L1196M gatekeeper mutant, for >95% of the 206 kinases tested .
To directly compare the potencies of PF-06463922, crizotinib, ceritinib, and alectinib in cell assays, NIH 3T3 and Ba/F3 cells were engineered to express either wild-type or the crizotinib-resistant mutants 1151Tins, L1152R, C1156Y, L1196M, G1269A, G1202R, F1174L, or S1206Y (Figures 1C and S1B ; Table S1 ). We observed a strong correlation between drug concentrations required to inhibit ALK phosphorylation and those needed to block ALK-dependent cell proliferation ( Figure 1C ). PF-06463922 was the most potent inhibitor against all clinically relevant crizotinib-, ceritinib-and/or alectinib-resistant ALK mutants. PF-06463922 showed strong ALK phosphorylation potency against the L1196M (half maximal inhibitory concentration [IC 50 ] = 15-43 nM) and G1269A (IC 50 = 14-80 nM) ALK mutants, which are two of the most frequently detected crizotinib-resistant mutations observed in the clinic Kim et al., 2013) . Furthermore, PF-06463922 demonstrated potent ALK phosphorylation activity against the 1151Tins (IC 50 = 38-50 nM) and G1202R (IC 50 = 77-113 nM) ALK mutants that confer a high level of resistance to all second-generation ALK inhibitors (Katayama et al., 2012; Shaw and Engelman, 2013) .
PF-06463922 Inhibits ALK-Dependent Cell Growth In Vitro
The activity of PF-06463922 on cell viability and intracellular signaling was examined in H3122 and H2228 ALK-positive lung cancer cell lines. In addition, we examined H3122 cells engineered to overexpress the crizotinib-resistant ALK mutants G1269A and L1196M. Similar to the Ba/F3 cell model, in these cell lines, PF-06463922 was greater than 30-fold more potent than crizotinib with respect to suppressing ALK-dependent signaling and inhibiting cell growth and inducing apoptosis (Figures 2A-2E and S2A-S2D; Table S1 ). Furthermore, the cell viability of in vitro-derived alectinib-resistant H3122 cells, which contain an endogenous V1180L ALK mutation , was sensitive to PF-06463922 via potent inhibition of ALK signaling ( Figures 2F and S2E) .
The efficacy of PF-06463922 was also examined in cell lines derived from patients with acquired resistance to crizotinib, ceritinib, or alectinib. These cells lines, SNU2535, MGH021-5, and MGH056-1, harbor endogenous EML4-ALK G1269A , SQSTM1- Figures 3A-3D ). In these experiments, PF-06463922 was administered by subcutaneous pump infusion, which better mimics the predicted human pharmacokinetic (PK) profile than oral dosing in mice (data not shown). Treatment with PF-06463922 led to a dose-dependent antitumor effect ranging from tumor growth inhibition (TGI) to tumor regression. The effect on tumor growth was consistent with its ability to dose-dependently inhibit ALK phosphorylation. A maximal effect of >95% inhibition of ALK phosphorylation was achieved in each of the models, and this resulted in tumor regression ranging from 35% to 77% ( Figure 3 ; Table S2 ). Of note, PF-06463922 significantly inhibited tumor growth in crizotinib-resistant models harboring mutant ALK, including the most resistant G1202R mutant.
A simple direct response PK-pharmacodynamic (PD) modeling analysis (Mager et al., 2003) was conducted to elucidate the relationship between PF-06463922 plasma concentration, inhibition of ALK phosphorylation, and suppression of tumor growth. The Hill equation showed reasonable fits for both inhibition of ALK phosphorylation and antitumor efficacy ( Figures  S3A-S3D ). The PK, PD, TGI, and Hill equation parameters of PF-06463922 from these studies are summarized in Tables S2  and S3 , and the efficacious concentration (Ceff) values derived from the Hill function analyses are summarized in Table S4 (Table S4 ). The Ceff (68 nM free) determined for the H3122 EML4-ALK L1196M model with PF-06463922 administered by infusion is similar to the Ceff (51 nM free) determined using the oral route (Yamazaki et al., 2014) . The Ceff values for maximum antitumor response for PF-06463922 correlated closely with the estimated 90% maximal effective concentration values for ALK phosphorylation inhibition in these tumors Table S4 ). An oral dosing study in the H3122-EML4-ALK L1196M model demonstrated significant tumor regression (35%) and greater than 95% inhibition of ALK phosphorylation in the 10 mg/kg twice daily (BID) group. The antitumor efficacy of the 10 mg/kg BID oral dosing schedule was similar to that of the 30 mg/kg once daily (QD) group (33% regression), and superior to the 10 mg/kg QD group (3% tumor regression) ( Figure S3E ). The 10 mg/kg BID group had lower unbound plasma maximal concentration (Cmax) (392 nM) than either the 10 mg/kg QD (1,636 nM) or the 30 mg/kg QD (3,193 nM) group, indicating that the antitumor efficacy of PF-06463922 was not driven by Cmax in this model (Table S2) . Collectively, these results indicate that near complete inhibition of ALK phosphorylation (>95%) with prolonged duration during the dosing interval by PF-06463922 is necessary to achieve maximal tumor regression, and PF-06463922 is able to achieve this activity at a relatively low dose.
PF-06463922 Drives Superior TGI In Vivo Compared with Crizotinib
The in vivo efficacy of PF-06463922 was directly compared with that of crizotinib in engineered H3122 models and patientderived cell lines. Consistent with in vitro data, PF-06463922 showed superior efficacy compared with crizotinib in tumor xenografts derived from H3122 EML4-ALK WT ( Figure S4A ), See also Figure S3 and Tables S2-S4. H3122 EML4-ALK L1196M ( Figure 4A ), and H3122 EML4-ALK G1269A cells (Figure S4B) . In parallel with tumor growth, PF-06463922 inhibited ALK-mediated signal transduction in tumor tissues collected 3 hr following the final dose of a 4-day treatment regimen to a greater extent than crizotinib. Specifically, ALK, AKT, ERK, STAT3, and S6 phosphorylation was significantly decreased by PF-06463922 in the respective H3122 EML4-ALK models ( Figures S4C-S4E ). These data corresponded to dose-dependent induction of cleaved caspase-3 levels measured in H3122 EML4-ALK L1196M tumor samples from mice treated with 3 and 10 mg/kg/day of PF-06463922 ( Figure 4B ). Of note, in H3122 EML4-ALK WT tumor-bearing mice, PF-06463922 showed similar efficacy in inhibiting tumor growth and ALK phosphorylation compared with alectinib ( Figures S4A and S4C) .
Two ALK-positive patient-derived cell lines were also used to evaluate the in vivo antitumor efficacy of PF-06463922 against wild-type EML4-ALK. MGH051 (EML4-ALK WT ) ( Figure 4C ) was derived from a crizotinib-resistant ALK-positive NSCLC patient . MGH006 (EML4-ALK WT ) ( Figure S4F ) was derived from a crizotinib-naive ALK-positive NSCLC patient (Katayama et al., 2012) . Oral administration of PF-06463922 potently suppressed ALK phosphorylation and led to substantial tumor regression of these xenograft models ( Figures S4G and S4H ).
The antitumor efficacy of PF-06463922 in xenograft models was durable. PF-06463922 suppressed subcutaneous tumor growth longer than 170 days in both MGH051 (EML4-ALK WT )
( Figure 4C ) and H3122-EML4-ALK G1269A ( Figure 4D ) and models at drug concentrations predicted to be clinically achievable. Moreover, PF-06463922 induced tumor regression in mice bearing MGH051 tumors that relapsed on crizotinib ( Figure 4C ).
PF-06463922 Induced Superior Regression of Intracranial EML4-ALK Tumors and Prolonged Mouse Survival Compared with Other Clinically Available ALK Inhibitors
Nearly 50% of ALK-positive NSCLC patients undergoing crizotinib treatment exhibit brain metastasis as the first site of disease progression, and in nearly 80% of these patients, systemic disease is under control (Camidge, 2013; Solomon et al., 2014b) . The physicochemical properties of PF-06463922 were specifically optimized to maximize its CNS availability. PF-06463922 demonstrated 21% to 31% free brain drug exposure relative to free plasma concentration in non-tumor-bearing rats and dogs and is predicted to penetrate the intact BBB in humans monitoring of tumor growth in vivo by either whole-body in vivo imaging systems (IVIS) or tail vein blood Gluc activity measurement, respectively. As shown by MRI ( Figures 5A and 5B), IVIS ( Figures S5A-S5C ) images, and blood Gluc activity measurements over time ( Figure 5C ), PF-06463922 demonstrated significant antitumor activity against H3122 EML4-ALK WT brain metastases that was superior to either crizotinib or alectinib. In subcutaneous studies, H3122 (EML4-ALK WT ) tumors displayed similar sensitivity to PF-06463922 and alectinib (Figure S4A) . However, although H3122 brain metastases relapsed between 40 and 120 days after alectinib initiation, PF-06463922 treatment suppressed tumor growth in all mice for the duration of the experiment (160 days). Interestingly, shifting the alectinib-relapsed mice to PF-06463922 induced a second tumor response in those animals, demonstrating that PF-06463922 has superior intracranial efficacy compared with alectinib ( Figure 5C ). The suppression in brain metastasis growth by PF-06463922 was consistent with better suppression of ALK phosphorylation ( Figure 5D ). Immunohistochemistry analysis indicated a significant reduction in the Ki67-positive tumor cell number and mitotic index in brain xenografts from mice within the 10 mg/kg BID treatment group ( Figures S5C and S5D) .
Consistent with the H3122 EML4-ALK WT brain metastasis study, PF-06463922 dose-dependently regressed H3122 EML4-ALK L1196M brain metastases at 5, 10, and 20 mg/kg/day, corresponding to median free brain drug concentrations of 35, 55, and 100 ng/g, respectively (Figures S5E and S5F) . In contrast, control-treated mice were euthanized, on average, 11 days after treatment initiation because of declining health attributed to tumor burden. See also Figure S5 .
We hypothesized that the superior inhibition of brain metastasis growth, attributed to better ALK kinase inhibition, was due to two factors: the enhanced potency of PF-06463922 and/or its increased ability to cross the BBB. To determine which mechanism attributed to its efficacy in our brain metastasis model, we tested an ALK inhibitor, PF-06439015, that possesses 1.5-fold greater potency than PF-06463922 but has poor CNS penetration (Huang et al., 2014; Johnson et al., 2014) . Continued subcutaneous infusion of PF-06463922 (6-12 mg/kg/day) suppressed brain tumor growth better than PF-06439015 (36 mg/kg/day) ( Figure S5B ). PK analysis from these studies indicated that the brain free fraction of PF-06463922 (0.30 ± 0.13) relative to free plasma concentration was >4-fold higher than that of PF-06439015 (0.07 ± 0.02) in mice bearing intracranial tumors. Similarly, better growth delay in the H3122 EML4-ALK L1196M brain metastasis model was attributed to better drug penetration, as PF-06439015 failed to control their growth as brain tumor drug concentrations reached only 9.5 ng/g (Figures S5E and S5F) .
Patient-derived MGH006 cells expressing Gluc were equally sensitive to crizotinib and PF-06463922 in subcutaneous studies ( Figure S4F ). When grown in the brain, however, PF-06463922 suppressed MGH006 tumor growth longer than crizotinib, leading to a significant improvement in survival ( Figures  5E and 5F ). Crizotinib delayed MGH006 brain metastasis growth roughly 3-fold compared with control-treated mice, but all mice were euthanized within 45 days after treatment initiation because of neurological defects consistent with large CNS tumors. At this time point, brain metastases from PF-06463922-treated mice were barely detectable and much smaller than when treatment was initiated. Consistent with their effects on brain metastasis growth, PF-06463922 achieved better suppression of ALK phosphorylation compared with crizotinib ( Figure 5G ). Furthermore, we observed reductions in total ALK levels in both treatment groups, but particularly after treatment with PF-06463922. It has been previously reported that HSP90 binding to ALK-fusion proteins in cells is disrupted by crizotinib treatment (Taipale et al., 2013) . This disruption may contribute to the reduction in total ALK-fusion protein levels.
PF-06463922 Demonstrated a Broad Therapeutic Window in Preclinical Studies
PF-06463922 demonstrated antitumor efficacy in both subcutaneous and brain orthotopic xenograft models harboring oncogenic ALK fusions containing either wild-type ALK or crizotinib-resistant ALK mutants at pharmacologically relevant doses. PF-06469322 was well tolerated in mice (lack of significant weight loss) at all doses used in our studies ( Figure S6 ). This safety profile is also reflected by in vitro cell assays. For example, compared with other ALK inhibitors, PF-06463922 demonstrated superior activity against ALK-fusion transformed Ba/F3 cells compared with other ALK inhibitors (Table S1 ), while displaying less toxicity to parental Ba/F3 cells (IC 50 > 10 mM) ( Figure 6A ). This finding is likely due to its high level of selectivity .
The lack of toxicity of PF-06463922 in Ba/F3 cells, in combination with its superior potency, suggests that this compound could achieve a strong preclinical safety margin. The preclinical safety profile of PF-06463922 was characterized through single-and repeat-dose studies of up to 1 month in duration in rats and dogs, as well as safety pharmacology and genetic toxicity studies. The nonclinical safety findings related to PF-06463922 were identified at reasonable exposure margins above the Ceff and represent toxicities that can be monitored and are reversible following a 1 month treatment-free period in rat and dog studies. PF-06463922 achieved a greater than 100-fold therapeutic index when comparing its Ceff (tumor stasis) in the EML4-ALK subcutaneous tumor growth model to its maximal tolerated dose (MTD) in both rats and dogs. The Ceff values derived from our in vivo studies are summarized in Table S4 . It is worth mentioning that PF-06463922 achieved a maximal effect for either ALK target inhibition or tumor regression in each of the tested efficacy models at exposure levels that are well below the MTD generated from 1 month dog or rat safety studies ( Figure 6B ). Because PF-06463922 is a brain-penetrable compound, the potential for adverse CNS effects were tested in repeated dose safety studies as well as in the rat contextual renewal model. No CNS-mediated signals were observed in these studies. Furthermore, the functional observation battery (FOB) assessment was included in the 1 month repeated dose study in the rat (data not shown). FOB is a series of noninvasive observational and interactive measures of CNS and automatic system function (e.g., body temperature, pupil response, gait, locomotor activity). No FOB effects were identified, despite achieving plasma exposures 60-fold higher than the predicted minimal efficacious exposure in humans (51 nM free), defined as the free compound concentration needed to achieve tumor stasis in the H3122 EML4-ALK L1196M model.
DISCUSSION
The discovery of oncogenic ALK fusions and the development of ALK targeted therapies, such as crizotinib, have transformed the course of disease for patients with ALK-driven cancers, particularly those with NSCLC. Patients derive significant benefit from either crizotinib or the second-generation inhibitors alectinib and ceritinib. However, the majority of patients invariably relapse, and limited treatment options remain after relapse.
Here we report preclinical data on PF-06463922, a next-generation ALK inhibitor that is currently in a phase 1 and 2 clinical trial (ClinicalTrials.gov identifier NCT01970865) for ALK or ROS1 fusion-positive NSCLC. In a variety of different ALK inhibitor resistant models, PF-06463922 demonstrated broad activity across ALK resistant mutations, including G1202R, which is the most refractory mutation identified to date. G1202R has rarely been reported in the setting of crizotinib resistance but is emerging as a common resistant mutation to the second-generation ALK inhibitors ceritinib or alectinib (Ignatius Ou et al., 2014) . This is consistent with our preclinical studies showing that G1202R confers broad resistance to first-and second-generation ALK inhibitors.
Although crizotinib has shown clinical activity against brain metastases, the CNS is a common site of relapse for patients on crizotinib (Costa et al., 2013 (Costa et al., , 2015 Solomon et al., 2014a Solomon et al., , 2014c . Mechanisms of resistance in the CNS to crizotinib have not been studied in detail, but one plausible mechanism is the inability of crizotinib to achieve therapeutic concentrations in the CNS compartment. Consistent with this notion, a case report showed low levels of crizotinib in the cerebrospinal fluid of a patient who had relapsed with brain metastases (Costa et al., 2011) . Poor brain penetration of crizotinib is likely due to its high efflux by P-glycoprotein (PGP) . Second-generation ALK inhibitors have shown moderate CNS activity, including patients who have relapsed on crizotinib (Gadgeel et al., 2014) . Similar to crizotinib, ceritinib is a PGP substrate and has limited brain penetration and therefore responses to ceritinib likely reflect its increased potency. Alectinib, on the other hand, is not a PGP substrate and is associated with an intracranial response rate of 52% (Gadgeel et al., 2014) . Nevertheless, patients treated with either ceritinib or alectinib still relapse with brain metastases, highlighting the need for a more potent inhibitor with increased CNS availability that, ideally, is not a substrate for PGP. PF-06463922 was specifically designed and optimized to efficiently penetrate the BBB, and as a result it showed 30% CNS availability in multiple preclinical species. We successfully mimicked the clinical situation in mouse models and showed that ALK fusion tumors, sensitive to crizotinib when growing subcutaneously, were resistant when growing in the brain parenchyma. Furthermore, PF-06463922 demonstrated superior efficacy to after alectinib relapse in our murine models of brain metastasis. PF-06463922 regressed intracranial tumors at doses much lower than the MTD in our preclinical studies. In contrast, a potent ALK inhibitor with low CNS availability (6%) failed to sustain TGI in the same intracranial tumor model, suggesting penetration into the brain metastasis plays a major role in the activity of PF-06463922. Although PF-06463922 provides hope that it will overcome brain metastases that develop in patients who relapse to first-and second-generation ALK inhibitors, data from the ongoing phase 1 study of PF-06463922 will be necessary to evaluate the CNS activity of PF-06463922 in humans, as preclinical studies may not predict brain penetration in humans.
The potency and safety profile, in combination with the penetration into the CNS, of PF-06463922 provides an opportunity to address both acquired and pharmacological mechanisms of drug resistance. Preclinical studies suggest a favorable preclinical safety window for PF-06463922 consistent with the ability to treat patients with drug exposures high enough to inhibit the most recalcitrant G1202R mutant and to reach therapeutic levels in the CNS. Preclinical studies are not always capable of predicting clinical toxicity, so data from the ongoing phase 1 study of PF-06463922 will be critical in understanding the safety margin that PF-06463922 can achieve in humans.
The most immediate impact of PF-06463922 may be on patients in whom previous ALK TKIs have failed, not only in systemic disease but also with brain metastases. Given that PF-06463922 is the most potent and brain-penetrable inhibitor that we tested in our models, whether it should be used as frontline treatment is an intriguing question that awaits clinical investigation. For example, could the frontline use of PF-06463922 lead to more durable responses than sequential therapy in the clinic, as suggested by the sustained responses seen with PF-06463922 in preclinical studies? Finally, if the safety and efficacy of PF-06463922 are confirmed in the clinic, PF-06463922 may serve as an ideal backbone for combination therapies aimed at overcoming and even preventing the emergence of resistant clones.
EXPERIMENTAL PROCEDURES Enzyme Assays and Compounds
Recombinant human wild-type and mutant ALK kinase domain proteins (amino acids 1093-1411) were produced in house using baculoviral expression, pre-activated via auto-phosphorylation with MgATP, and assayed for kinase activity using a microfluidic mobility shift assay. The reactions contained 1.3 nM wild-type ALK or 0.2 to 10 nM mutant ALK (appropriate to produce 15%-20% phosphorylation of peptide substrate after 1 hr reaction), 3 mM 5-FAM-KKSRGDYMTMQIG-CONH2, 5 mM MgCl 2 , and the Km-level of ATP in 25 mM HEPES (pH 7.1). The K i values were calculated by fitting the percentage conversion to a competitive inhibition equation (GraphPad Prism; GraphPad Software). PF-06463922 and PF-06439015 were synthesized as described in Huang et al. (2014) and Johnson et al. (2014) , respectively, and PF-02341066 as described in Cui et al. (2011) . The physical properties of PF-06463922 were specifically optimized to maximize CNS availability by controlling molecular weight, lipophilicity, and hydrogen bond donor count.
Cell Culture and Reagents NCI-H3122 human NSCLC cells were licensed from the National Institutes of Health (NIH). Karpas299 and NIH 3T3 cells were purchased from American Tissue Culture. BaF3 cells were obtained from DSMZ. NCI-H3122 and NCI-H2228 are human lung adenocarcinoma cell lines harboring the EML4-ALK fusion protein variant 1 (V1) and variant 3 (V3a/b), respectively. The SNU2535, MGH056-1, and MGH021-5 NSCLC cell lines were derived from crizotinib-, alectinib-, or ceritinib-relapsed patients and harbor the mutant ALK fusion proteins G1269A, I1171T, and G1202R, respectively. MGH006, MGH051-1, MGH021-5, and MGH056-1 were maintained as previously described Katayama et al., 2012 Katayama et al., , 2014 Kim et al., 2013) . Cell culture reagents were obtained from Life Technologies. Cells were maintained at 37 C in a humidified atmosphere with 5% to 10% CO 2 .
Engineered Cell Line Generation
The target of interest was first cloned into the retroviral vector pMSCV puro or pMSCVhygro. The retroviruses carrying recombinant genes were produced in 293T cells by co-transfection with the pMSCV vectors and the packaging plasmid pCL10A1. The retroviral supernatants were used to transduce NCI-H3122, NIH 3T3, or BaF3 parental cells, and pooled populations were selected with 2 mg/l puromycin or 50 mg/l hygromycin for 5 days.
Cell-Based Kinase Phosphorylation ELISAs
Cells were seeded in 96-well plates in growth media with 0.5% fetal bovine serum and incubated overnight. Compounds were diluted in media without serum, added to the cells, incubated for 1 hr, and then removed by aspirating the media by vacuum suction. Cell lysates were generated and the phospho-ALK (Tyr1604) levels were determined by using the PathScan Phospho-ALK (Tyr1604) Chemiluminescent Sandwich ELISA Kit (Cell Signaling) or PathScan Total ALK Chemiluminescent Sandwich ELISA Kit (Cell Signaling), as described in the manufacturer's protocol. IC 50 values were calculated by concentration-response curve fitting using a four-parameter analytical method. This phospho-ALK ELISA was also used to determine phosphor-ALK levels in the protein extracts from xenograft tumor samples.
Cell Proliferation Assay
Cells were seeded in 96-well plates in growth media containing 10% fetal bovine serum (FBS) and cultured overnight at 37 C. The following day, serial dilutions of PF-06463922 or appropriate controls were added to the designated wells, and cells were incubated at 37 C for 72 hr. A Cell Titer Glo assay (Promega) was then performed to determine the relative cell numbers. IC 50 values were calculated by concentration-response curve fitting using a fourparameter analytical method.
Cell Caspase-3/7 Activity Assay Cells were seeded in 96-well plates at 15,000 cells/well in RPMI media supplemented with 0.5% FBS (Assay Media) and allowed to adhere overnight at 37 C. The following day, 10 mM PF-06463922 was serially diluted in DMSO, and the DMSO dilutions were further diluted in Assay Media and added to the designated wells resulting in a range of serially diluted concentrations of PF-06463922 in the media with 0.5% serum and 0.1% DMSO. The cells were incubated for 24 hr, and the caspase-3/7 activity was measured using the Caspase-Glo 3/7 Assay Kit (Promega), as described in the manufacturer's protocol. IC 50 values were calculated by concentration-response curve fitting using a four-parameter analytical method. 
Drug Administration
In all tumor xenograft studies, the compound of interest was administered either orally at 5 to 10 ml/kg using sterile 20-gauge feeding needles (Popper and Sons) or with a subcutaneous Alzet mini-pump (Durect) infusion.
Subcutaneous Tumor Model
The cells were supplemented with 50% Matrigel (BD Biosciences) to facilitate tumor take. Cells (5 3 10 6 in 100 ml) were implanted subcutaneously into the hind flank region of the mouse and allowed to grow to the designated size prior to the administration of compound for each experiment. Tumor size was determined by measurement with electronic calipers, and tumor volume was calculated as length 3 width 2 3 0.4.
Intracranial Tumor Model
For injection into the brain, the head of the mouse was fixed with a stereotactic apparatus, and the skull over the left hemisphere of the brain was exposed via skin incision. Using a high-speed air-turbine drill (CH4201S; Champion Dental Products) with a burr tip size of 0.5 mm in diameter, three sides of a square (2.5 mm in length, each side) were drilled through the skull until a bone flap became loose. Using blunt tweezers, the bone flap was pulled back, exposing the brain parenchyma. One hundred thousand cancer cells, diluted in 1 ml PBS, were stereotactically injected into the left frontal lobe of the mice. The bone flap was then placed back into position in the skull and sealed using histocompatible cyanoacrylate glue, and the skin atop the skull was sutured closed. Brain metastatic tumor growth was measured through the use of Gluc, an in vivo secreted reporter expressed by tumor cells and measured in the peripheral blood. In similar models, the blood Gluc activity directly correlated with tumor volume (Kodack et al., 2012) .
MRI Study
Magnetic resonance images were acquired with a Bruker 7.0 T scanner with an Avance II console using a 72 mm inside diameter linear birdcage resonator for transmission and a two-element surface coil array for local reception. Pre-and post-contrast T1-weighted fast spin-echo images were acquired. While in the scanner, the temperature and respiratory trace of each mouse were monitored continuously. The isoflurane-oxygen mixture (1.4%-2.0%) was adjusted on the basis of the respiratory rate. The mouse temperature was stabilized by forced-air heating with automatic feedback from a rectal temperature probe. Before post-contrast scans, mice were injected with gadolinium. Injections were timed such that image acquisition coincided with a period of stable tumor contrast, as determined in a pilot study. Tumor volume was calculated by manual segmentation of T1-weighted images using ImageJ software (NIH).
Ex Vivo Target Modulation (PK/PD) Studies
For tissue and plasma processing for PK/PD studies, mice were humanely euthanized, blood and brain tissue samples were collected for PK analysis, and tumors were resected for PD analysis. Plasma and brain samples were analyzed for PF-06463922 concentration using liquid chromatography mass spectrometry analysis. Resected tumors were snap-frozen and pulverized on a liquid nitrogen cooled cryomortar and pestle, and lysed in cold 1X Cell Lysis Buffer (Cell Signaling Technologies). Proteins were extracted from tumor lysate, and protein concentrations were determined using a BSA assay (Pierce). The level of phosphorylated ALK in each tumor sample was determined using the capture ELISA or western blotting method.
Immunoblotting
The immunoblotting method was also used to determine relative kinase phosphorylation status and total protein levels in cells and tumor tissues for the protein of interest. Extracted protein samples from cells or tumor lysates were separated by SDS-PAGE and transferred to nylon membranes, and immunoblotting hybridizations for the proteins of the interest were performed using the corresponding antibodies. Phospho-ERK (T202/Y204), ERK, S6, phospho S6, phospho-AKT (S473 and T308), AKT, phospho-ALK (Y1282/ 1283), and ALK antibodies were obtained from Cell Signaling Technology. GAPDH was purchased from Millipore.
Statistics
Sample size for in vivo TGI studies was estimated to be about n = 8 to 12 per group to ensure 80% power to capture 70% TGI in a one-sided test on the basis of variability estimate from historical data. Animals were randomized into different treatment groups stratified on their initial tumor size, so the average tumor size for each group was similar at baseline. Standard inclusion and exclusion criteria were used whereby animals were excluded only in rare occasions (such as death) after randomization. Investigators were not blinded to treatment assignment. Because of skewed distribution of the tumor volume data, ANOVA models were fit to the rank-transformed tumor volume. Individual comparisons between treatment groups and vehicle group or among the treatment groups were assessed withone1-sided least significant difference tests and, all under the ANOVA model for ranks.
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